US Bancorp DE Has $2.13 Million Position in HealthEquity, Inc. $HQY

US Bancorp DE boosted its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 10.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,351 shares of the company’s stock after buying an additional 2,001 shares during the period. US Bancorp DE’s holdings in HealthEquity were worth $2,132,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Invesco Ltd. lifted its holdings in HealthEquity by 50.6% in the first quarter. Invesco Ltd. now owns 2,446,198 shares of the company’s stock valued at $216,171,000 after buying an additional 821,425 shares during the period. Goldman Sachs Group Inc. lifted its holdings in HealthEquity by 1.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,133,166 shares of the company’s stock valued at $100,138,000 after buying an additional 15,458 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in HealthEquity by 1.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,100,970 shares of the company’s stock valued at $97,293,000 after buying an additional 14,159 shares during the period. Stephens Investment Management Group LLC lifted its holdings in HealthEquity by 1.8% in the first quarter. Stephens Investment Management Group LLC now owns 1,069,446 shares of the company’s stock valued at $94,507,000 after buying an additional 19,009 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in HealthEquity by 24.9% in the first quarter. Wellington Management Group LLP now owns 848,940 shares of the company’s stock valued at $75,021,000 after buying an additional 169,337 shares during the period. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at HealthEquity

In other news, EVP Delano Ladd sold 6,000 shares of the firm’s stock in a transaction dated Friday, September 19th. The shares were sold at an average price of $94.11, for a total transaction of $564,660.00. Following the completion of the sale, the executive vice president owned 79,456 shares in the company, valued at approximately $7,477,604.16. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Henry Fiore sold 1,781 shares of the firm’s stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $88.21, for a total transaction of $157,102.01. Following the transaction, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on HQY. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $120.00 target price (up previously from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. Barrington Research reaffirmed an “outperform” rating and issued a $125.00 target price on shares of HealthEquity in a research note on Friday, August 29th. Jefferies Financial Group upped their target price on shares of HealthEquity from $130.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, September 3rd. JPMorgan Chase & Co. upped their target price on shares of HealthEquity from $125.00 to $126.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of HealthEquity in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $121.31.

HealthEquity Stock Performance

NASDAQ HQY opened at $92.55 on Thursday. The firm has a 50-day moving average of $91.75 and a 200-day moving average of $93.94. The company has a debt-to-equity ratio of 0.47, a quick ratio of 4.23 and a current ratio of 4.23. The stock has a market cap of $7.97 billion, a PE ratio of 56.09, a P/E/G ratio of 1.35 and a beta of 0.47. HealthEquity, Inc. has a 52-week low of $74.07 and a 52-week high of $116.65.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Tuesday, September 2nd. The company reported $0.92 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.92. The company had revenue of $325.80 million during the quarter, compared to analysts’ expectations of $320.68 million. HealthEquity had a net margin of 11.49% and a return on equity of 12.04%. HealthEquity has set its FY 2026 guidance at 3.740-3.91 EPS. On average, sell-side analysts anticipate that HealthEquity, Inc. will post 2.32 EPS for the current year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.